Vir Biotechnology, Inc.
VIR
$5.50
$0.0651.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 74.21M | 78.62M | 78.88M | 79.60M | 86.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 74.21M | 78.62M | 78.88M | 79.60M | 86.18M |
| Cost of Revenue | 489.37M | 506.95M | 456.78M | 519.72M | 579.09M |
| Gross Profit | -415.16M | -428.33M | -377.91M | -440.12M | -492.91M |
| SG&A Expenses | 118.98M | 133.50M | 148.69M | 163.94M | 174.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 608.35M | 640.45M | 605.47M | 683.66M | 753.53M |
| Operating Income | -534.14M | -561.83M | -526.60M | -604.06M | -667.35M |
| Income Before Tax | -523.11M | -539.19M | -492.27M | -550.01M | -628.19M |
| Income Tax Expenses | -1.15M | -5.84M | -9.23M | -10.57M | -13.08M |
| Earnings from Continuing Operations | -521.96 | -533.34 | -483.04 | -539.44 | -615.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 0.00 | 0.00 | 0.00 | 56.00K |
| Net Income | -521.96M | -533.34M | -483.04M | -539.44M | -615.06M |
| EBIT | -534.14M | -561.83M | -526.60M | -604.06M | -667.35M |
| EBITDA | -519.59M | -545.68M | -508.75M | -585.73M | -647.90M |
| EPS Basic | -3.83 | -3.92 | -3.58 | -4.01 | -4.59 |
| Normalized Basic EPS | -2.13 | -2.24 | -2.06 | -2.41 | -2.75 |
| EPS Diluted | -3.83 | -3.93 | -3.58 | -4.02 | -4.59 |
| Normalized Diluted EPS | -2.13 | -2.24 | -2.06 | -2.41 | -2.75 |
| Average Basic Shares Outstanding | 544.98M | 542.78M | 540.41M | 538.24M | 536.51M |
| Average Diluted Shares Outstanding | 544.98M | 542.78M | 540.41M | 538.24M | 536.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |